针对癌症中的细胞周期机制。
Targeting cell-cycle machinery in cancer.
机构信息
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Department of Pathology, Chair of Oncology, Medical University of Lodz, 92-213 Lodz, Poland.
出版信息
Cancer Cell. 2021 Jun 14;39(6):759-778. doi: 10.1016/j.ccell.2021.03.010. Epub 2021 Apr 22.
Abstract
Abnormal activity of the core cell-cycle machinery is seen in essentially all tumor types and represents a driving force of tumorigenesis. Recent studies revealed that cell-cycle proteins regulate a wide range of cellular functions, in addition to promoting cell division. With the clinical success of CDK4/6 inhibitors, it is becoming increasingly clear that targeting individual cell-cycle components may represent an effective anti-cancer strategy. Here, we discuss the potential of inhibiting different cell-cycle proteins for cancer therapy.
摘要
核心细胞周期机制的异常活动几乎可见于所有肿瘤类型，是肿瘤发生的驱动力。最近的研究表明，细胞周期蛋白除了促进细胞分裂外，还调节着广泛的细胞功能。随着 CDK4/6 抑制剂的临床成功，靶向单个细胞周期成分可能代表一种有效的抗癌策略，这一点变得越来越清楚。在这里，我们讨论了抑制不同细胞周期蛋白用于癌症治疗的潜力。
相似文献
1
Targeting cell-cycle machinery in cancer.针对癌症中的细胞周期机制。
Cancer Cell. 2021 Jun 14;39(6):759-778. doi: 10.1016/j.ccell.2021.03.010. Epub 2021 Apr 22.
2
CDK4 and CDK6 kinases: From basic science to cancer therapy.CDK4 和 CDK6 激酶：从基础科学到癌症治疗。
Science. 2022 Jan 14;375(6577):eabc1495. doi: 10.1126/science.abc1495.
3
Targeting CDK4 and CDK6: From Discovery to Therapy.靶向细胞周期蛋白依赖性激酶4和6：从发现到治疗
Cancer Discov. 2016 Apr;6(4):353-67. doi: 10.1158/2159-8290.CD-15-0894. Epub 2015 Dec 11.
4
Cyclin D-CDK4/6 functions in cancer.细胞周期蛋白 D-CDK4/6 在癌症中的作用。
Adv Cancer Res. 2020;148:147-169. doi: 10.1016/bs.acr.2020.02.002. Epub 2020 Apr 2.
5
Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.分子通路：针对癌症治疗的细胞周期蛋白 D-CDK4/6 轴。
Clin Cancer Res. 2015 Jul 1;21(13):2905-10. doi: 10.1158/1078-0432.CCR-14-0816. Epub 2015 May 4.
6
Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.细胞周期蛋白依赖性激酶 4/6 抑制剂耐药机制。
Mol Biol Rep. 2021 Jan;48(1):915-925. doi: 10.1007/s11033-020-06100-3. Epub 2021 Jan 7.
7
SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.SPH3643：一种新型细胞周期蛋白依赖性激酶 4/6 抑制剂，具有良好的抗癌疗效和较强的血脑屏障通透性。
Cancer Sci. 2020 May;111(5):1761-1773. doi: 10.1111/cas.14367. Epub 2020 Mar 24.
8
CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.CDK4/6 和自噬抑制剂协同诱导 Rb 阳性细胞质 cyclin E 阴性癌症衰老。
Nat Commun. 2017 Jun 27;8:15916. doi: 10.1038/ncomms15916.
9
CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy.CDK4、CDK6/细胞周期蛋白 D1 复合物抑制与放疗在癌症控制中的作用：自噬的角色。
Int J Mol Sci. 2021 Aug 4;22(16):8391. doi: 10.3390/ijms22168391.
10
The application and prospect of CDK4/6 inhibitors in malignant solid tumors.CDK4/6 抑制剂在恶性实体瘤中的应用及前景。
J Hematol Oncol. 2020 May 1;13(1):41. doi: 10.1186/s13045-020-00880-8.
引用本文的文献
1
Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells.癌细胞中保守残基的获得性突变导致对CDK7抑制剂产生抗性。
EMBO J. 2025 Sep 8. doi: 10.1038/s44318-025-00554-6.
2
Mechanistic modeling of cell viability assays with in silico lineage tracing.采用计算机模拟谱系追踪的细胞活力测定的机制建模
PLoS Comput Biol. 2025 Aug 29;21(8):e1013156. doi: 10.1371/journal.pcbi.1013156. eCollection 2025 Aug.
3
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors.使用细胞周期蛋白A/B RxL抑制剂靶向G1-S期检查点功能受损的癌症。
Nature. 2025 Aug 20. doi: 10.1038/s41586-025-09433-w.
4
Harnessing multi-omics and artificial intelligence: revolutionizing prognosis and treatment in hepatocellular carcinoma.利用多组学和人工智能：革新肝细胞癌的预后和治疗
Front Immunol. 2025 Jul 23;16:1592259. doi: 10.3389/fimmu.2025.1592259. eCollection 2025.
5
Ginkgetin from Ginkgo biloba: mechanistic insights into anticancer efficacy.银杏中的银杏双黄酮：抗癌功效的作用机制洞察
Nat Prod Bioprospect. 2025 Aug 5;15(1):50. doi: 10.1007/s13659-025-00535-6.
6
Traditional Chinese medicine in the treatment of breast Cancer.中医治疗乳腺癌
Mol Cancer. 2025 Aug 1;24(1):209. doi: 10.1186/s12943-025-02416-5.
7
A prognostic signature for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.激素受体阳性、人表皮生长因子受体2阴性乳腺癌的预后标志物
Sci Rep. 2025 Jul 22;15(1):26617. doi: 10.1038/s41598-025-11221-5.
8
PFKM phosphorylates histone H3 and promotes mitotic progression by sensing the levels of citrate.磷酸果糖激酶M（PFKM）使组蛋白H3磷酸化，并通过感知柠檬酸水平促进有丝分裂进程。
Nat Commun. 2025 Jul 22;16(1):6736. doi: 10.1038/s41467-025-62111-3.
9
Thymus serpyllum extract exerts anticancer activities against colorectal cancer by modulating metastasis, cell cycle arrest, and apoptosis.百里香提取物通过调节转移、细胞周期阻滞和凋亡对结直肠癌发挥抗癌活性。
Mol Biol Rep. 2025 Jul 18;52(1):732. doi: 10.1007/s11033-025-10838-z.
10
A Trade-Off between Body Mass and Cancer Resistance in Cetaceans Is Mediated by Cell Cycle-Related Gene Evolution.鲸类动物体重与抗癌能力之间的权衡由细胞周期相关基因进化介导。
Mol Biol Evol. 2025 Jul 1;42(7). doi: 10.1093/molbev/msaf159.
本文引用的文献
1
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.帕博西尼联合辅助内分泌治疗早期乳腺癌（PALLAS）：多中心、开放标签、随机、III 期研究的中期分析。
Lancet Oncol. 2021 Feb;22(2):212-222. doi: 10.1016/S1470-2045(20)30642-2. Epub 2021 Jan 15.
2
Ubiquitin signaling in cell cycle control and tumorigenesis.泛素信号在细胞周期调控和肿瘤发生中的作用。
Cell Death Differ. 2021 Feb;28(2):427-438. doi: 10.1038/s41418-020-00648-0. Epub 2020 Oct 31.
3
The requirement for cyclin E in c-Myc overexpressing breast cancers.cyclin E 在 c-Myc 过表达型乳腺癌中的需求。
Cell Cycle. 2020 Oct;19(20):2589-2599. doi: 10.1080/15384101.2020.1804720. Epub 2020 Sep 25.
4
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).阿贝西利联合内分泌治疗用于 HR+、HER2-、淋巴结阳性、高危、早期乳腺癌的辅助治疗（monarchE）。
J Clin Oncol. 2020 Dec 1;38(34):3987-3998. doi: 10.1200/JCO.20.02514. Epub 2020 Sep 20.
5
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition.溶酶体生物量增加是三阴性乳腺癌对CDK4/6抑制产生抗性的原因。
Sci Adv. 2020 Jun 17;6(25):eabb2210. doi: 10.1126/sciadv.abb2210. eCollection 2020 Jun.
6
Targeted protein degradation as a powerful research tool in basic biology and drug target discovery.靶向蛋白降解作为基础生物学和药物靶点发现的有力研究工具。
Nat Struct Mol Biol. 2020 Jul;27(7):605-614. doi: 10.1038/s41594-020-0438-0. Epub 2020 Jun 15.
7
A novel landscape of nuclear human CDK2 substrates revealed by in situ phosphorylation.原位磷酸化揭示的核人类细胞周期蛋白依赖性激酶2底物的全新格局。
Sci Adv. 2020 Apr 17;6(16):eaaz9899. doi: 10.1126/sciadv.aaz9899. eCollection 2020 Apr.
8
Pharmacogenomic Analysis Reveals as a Predictive Biomarker of Sensitivity to Polo-Like Kinase I Inhibitor in Gastric Cancer.药物基因组学分析揭示 作为胃癌中对Polo样激酶I抑制剂敏感性的预测生物标志物。 （注：原文中“Reveals”后缺少具体内容）
Cancers (Basel). 2020 May 30;12(6):1418. doi: 10.3390/cancers12061418.
9
Development of CDK2 and CDK5 Dual Degrader TMX-2172.开发 CDK2 和 CDK5 双降解剂 TMX-2172。
Angew Chem Int Ed Engl. 2020 Aug 10;59(33):13865-13870. doi: 10.1002/anie.202004087. Epub 2020 Jun 3.
10
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.激素受体阳性转移性乳腺癌患者中细胞周期蛋白依赖性激酶 4/6 抑制剂的内在和获得性耐药的基因组特征
Cancer Discov. 2020 Aug;10(8):1174-1193. doi: 10.1158/2159-8290.CD-19-1390. Epub 2020 May 13.
Zotero 插件